Celltrion Healthcare announced new 1-year data from a randomised controlled trial to evaluate the pharmacokinetics (PK), efficacy and safety of CT-P13 subcutaneous (SC) formulation compared to the CT-P13 intravenous (IV) formulation in patients with active Crohn’s disease (CD) and ulcerative colitis (UC).
The Janssen Pharmaceutical Companies of Johnson & Johnson announced interim data from the Phase 3b STARDUST study. At week 16, 79 percent of patients with moderately to severely active Crohn’s disease (CD) achieved clinical responsea and 67 percent were in clinical remissionb after receiving one ~6 mg/kg intravenous (IV) dose followed by one 90 mg subcutaneous (SC) dose of STELARA® (ustekinumab), open label.
Merck’s Keytruda in combination with chemotherapy has achieved the primary endpoint of progression-free survival (PFS) as first-line treatment for metastatic triple-negative breast cancer (mTNBC) in the phase 3 KEYNOTE-355 trial.
Pfizer and Astellas Pharma announced that Xtandi (enzalutamide) has shown significant improvement in overall survival (OS) in phase 3 PROSPER trial.
Eli Lilly and Company (Lilly) said that its anti-amyloid monoclonal antibody solanezumab failed to meet the primary endpoint in the phase 2/3 Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study.
Moderna, a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced that the Phase 2 dose-confirmation study of its mRNA vaccine against cytomegalovirus (CMV) is enrolling ahead of plan with data now expected in the third quarter of 2020.
Biohaven Pharmaceutical Holding reported negative topline results from its Phase 3 clinical trial evaluating troriluzole compared to placebo for the treatment of patients with Generalized Anxiety Disorder (GAD).
Regeneron Pharmaceuticals said that a phase 3 trial assessing Eylea (aflibercept) Injection 2 mg (0.05 mL) in moderately severe to severe non-proliferative diabetic retinopathy (NPDR) has yielded positive two-year results.
Elios Therapeutics presented a subgroup analysis of the prospective, randomized, double-blind, placebo-controlled Phase IIb clinical trial evaluating its personalized tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine, in patients with Stage III and IV resected melanoma.
Rebiotix, a Ferring company, announced today that it has completed enrollment of the pivotal Phase 3 clinical trial for RBX2660, an investigational therapy aimed at breaking the cycle of recurrent Clostridioides difficile (C. diff) infection, which is responsible for the deaths of thousands of people in the US alone.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.